Document:

Exhibit 10.24

 

 

CLINICAL RESEARCH AGREEMENT

 

THIS CLINICAL RESEARCH AGREEMENT (CRA or Agreement) is entered into effective as of October 26, 2018, between TKL Research, Inc., having its principal place of business at One Promenade Boulevard, Suite 1101/1201, Fair Lawn, New Jersey 07410 (TKL) and Agile Therapeutics, Inc. (Sponsor) having its principal place of business at 101 Poor Farm Road, Princeton, New Jersey 08540 (Sponsor) (together the “Parties”).

 

Section 1 - General Statement of Agreement

 

This Agreement sets forth the terms and conditions upon which TKL shall supply Sponsor with clinical research services (the “Services”).

 

Section 2 - Description of Services

 

TKL will perform clinical research studies (Study) for Sponsor during the term of this Agreement in accordance with mutually-approved written Protocols in which case the Protocol will be provided by Sponsor or prepared by TKL at Sponsor’s request and the Protocol will specify the Study design, information desired, estimated duration of the Study and all other relevant matters.  TKL will allocate qualified and properly trained staff as appropriate for each study to assure the study will be executed according to schedule. The Protocol will not be changed without prior written consent of the parties.  Protocols prepared by TKL are subject to Sponsor’s approval.

 

Section 3 - Statements of Work

 

The terms and conditions of this Agreement shall govern the performance of Services, including but not limited to services pertaining to clinical trials, by TKL for Sponsor under any individual statement of work document (each a “SOW”) entered into between TKL and Sponsor.  Each SOW shall be substantially in the form of Exhibit A-1 to this Agreement.  Each SOW shall be numbered in accordance with the number of the related project (each, a “Project”) and clinical trial (each, a “Clinical Trial”) to which it applies. If the SOW is not explicitly related to a Clinical Trial, it shall be identified by a unique Project name. Each SOW, when signed by each party, shall be deemed to form an integral part of this Agreement and shall be incorporated herein by this reference.  If any term in a SOW conflicts with this Agreement, this Agreement will control except to the extent that the SOW expressly states that such conflicting term prevails over this Agreement.

 

Section 4 - Term of Agreement

 

The term of this Agreement shall begin on the date of this Agreement as set forth above and shall continue for a period of five (5) years from such date unless the term is extended by mutual written agreement of the parties, or the Agreement is terminated as described in Section 6 - Termination.  Any SOW, the duration of which extends beyond the expiration or termination of this Agreement, will continue to be performed for the term of such SOW, and will continue to be governed by the terms of this Agreement, which terms shall remain in effect beyond the expiration or termination of this Agreement solely with respect to such SOW.

 

Section 5 - Financial Consideration and Payment Schedule

 

The total payment or payments which Sponsor will be obligated to make or cause to be made to TKL to complete each Study shall be set forth in the applicable SOW.  At the end of each month, TKL shall submit an invoice for payments due according to the schedule set forth in the applicable SOW, and payments shall be remitted to TKL within 30 days from receipt of invoice by the Sponsor.

 

201.587.0500  ·  www.tklresearch.com

 

 

TKL Research, Inc. One Promenade Boulevard, Suite 1101/1201, Fair Lawn, NJ 07410

 

1

 

Section 6 - Termination

 

The Sponsor has the right to terminate this Agreement and/or any individual SOW at any time with or without cause upon thirty (30) days written notice to TKL.  Either party may immediately terminate this Agreement and/or any individual SOW for a material breach of this Agreement or the applicable SOW by the other party (the “Breaching Party”), provided that the Breaching Party fails to cure such material breach within thirty (30) days after receipt of written notice specifying such material breach.

 

If the Sponsor terminates the study, with or without cause, with at least fifteen (15) days notice before the scheduled date of initiation, the Sponsor shall reimburse TKL for its actual, documented losses (the TKL losses) incurred in preparation for that study which include but are not limited to incurred and non-cancellable expenses associated with protocol design and preparation, recruiting, scheduling, advertising, planning, overhead costs and other costs, expenses and losses incurred by TKL.  If the Sponsor terminates the study with less than fifteen (15) days notice before the scheduled date of initiation, the Sponsor shall reimburse TKL for its actual losses as described above, plus 15% of the study fee.  If the Sponsor terminates the study after the study has been initiated, the Sponsor shall reimburse TKL for its actual losses, plus 25% of the study fee.

 

Upon the expiration or termination of this Agreement or any SOW, TKL shall as soon as practically possible turn over all Services- or Study-related documentation and materials in its possession, including, without limitation, Sponsor’s Confidential Information, study drug and other study materials, and documents created in performing of the Services or individual Study, as applicable.

 

Termination of this Agreement and/or of any individual SOW for any reason shall not affect the rights of the parties that have accrued on or before termination.

 

Section 7 – Termination Assistance

 

TKL shall provide the services in progress immediately prior to termination of such SOW for a period (the “Termination Assistance Services”) of up to thirty (30) days (the “Termination Assistance Period”)and be entitled to compensation on an hourly rate basis for the individuals performing such work (in accordance with the schedule of hourly rates furnished to Sponsor in connection with the applicable SOW); thereafter TKL shall have no further obligation with respect to Termination Assistance Services.  The Parties shall agree to a detailed plan for the performance of the Termination Assistance Services.

 

Section 8- Delays

 

If the Sponsor delays the scheduled initiation of the study by more than one (1) week the Sponsor shall give prompt notice of such delay to TKL and reimburse TKL for its non-recoverable losses incurred in preparation for the study, including but not limited to recruiting and advertising, MD fees, and commitments to sub-contractors.

 

Section 9- Confidentiality

 

TKL shall maintain in confidence and use only for the purposes contemplated in this Agreement or any SOW (1) data and information which is disclosed by or on behalf of Sponsor to TKL and (2) research data and information which is generated as the result of any Study (the “Extended Confidential Information”) (together the “Confidential Information”).  The preceding obligation shall not apply to data or information which has entered the public domain through no fault of TKL or

 

2

 

where Sponsor agrees in writing to its use or disclosure.  TKL agrees to return Confidential Information and all copies thereof at the conclusion of each Study or at an earlier date at the request of the Sponsor, except with respect to raw research Study data where original data will be retained in accordance with United States Food and Drug Administration regulation (or as otherwise required by law).  TKL agrees not to publish, disclose or otherwise reveal to others for a period of ten (10) years after termination or expiration of this Agreement without the permission of the Sponsor any proprietary or Confidential Information unless the information is (a) through no fault of TKL, subsequently published or disclosed publicly by a third party who is not restricted from making such disclosure by any direct or indirect obligation of confidentiality to Sponsor, (b) is required to be disclosed by under a facially valid court order, warrant or subpoena, or litigation request, but only (i) to the extent of such court order, warrant, subpoena, or litigation request and (ii) if TKL first gives Sponsor immediate oral and written notice of the court order, warrant, subpoena, or litigation request to permit Sponsor to take appropriate legal action in the circumstances.

 

TKL shall hold the Extended Protection Confidential Information in strict confidence and shall not disclose any Extended Protection Confidential Information to any person or entity; provided that Extended Protection Confidential Information may be disclosed to officers, employees, or agents of TKL (collectively, the “Representatives”) who (a) have a need to know the Extended Protection Confidential Information in connection with performance of the Services and only then to the extent required for the Representatives to perform their obligations in connection with the Services, (b) have been informed by TKL of the confidential nature of the Extended Protection Confidential Information and of the confidentiality undertakings of TKL contained herein.  TKL represents and warrants that each Representative has signed a confidentiality agreement containing clauses as least as restrictive as the confidentiality obligations contained herein.  TKL shall use commercially reasonable efforts to limit the number of Representatives that have access to the Extended Protection Confidential Information.  Upon written request by Sponsor, TKL shall provide Sponsor with a list of the names and titles of all Representatives that received access to the Extended Protection Confidential Information.  TKL shall be responsible for any breach of this provision by its Representatives.  TKL shall promptly notify Sponsor of any unauthorized release of, access to or use of Extended Protection Confidential Information.  TKL covenants that it shall maintain security practices designed to meet generally accepted industry practice and are designed to ensure the security, confidentiality and integrity of the Extended Protection Confidential Information.

 

Section 10 - Reporting of Data

 

TKL agrees to provide Sponsor periodically, as set forth in each SOW, and in timely manner during the term of this Agreement with the data called for in each Protocol on properly completed case report forms and will compile such data in one final written report for each Study which will be submitted to Sponsor in TKL’s standard format along with a complete copy of all research data generated during the course of the Study within approximately thirty (30) days of termination of that Study.  If the Sponsor requires changes in the report format or a customized format, which requires TKL to expend additional effort, time and expense, Sponsor will reimburse TKL for the additional costs which are incurred by TKL.  TKL agrees to notify Sponsor immediately by telephone after learning of a serious adverse experience or suspected drug reaction of any subject in any Study and to provide written notice of such experience or reaction within three (3) days of its occurrence.

 

3

 

Section 11 - Insurance

 

TKL maintains insurance coverage for:

 

	
Professional Liability
    	
$3 million/ $5 million   aggregate
    
	
Employment Practices   Liability
    	
$1 million/ $3 million   aggregate
    
	
Automobile Liability
    	
$1 million
    
	
Commercial General   Liability
    	
$1 million / $2 million   aggregate
    
	
Workers’ Compensation
    	
as required by law -   $1million
    
	
Commercial Umbrella   Liability
    	
$25 million / $25   million aggregate
    

 

Most Physicians/Principal Investigators carry and maintain professional medical liability insurance with limits of not less than $1,000,000 per medical incident and $3,000,000 per medical aggregate for performing services under this Agreement. If requested, TKL shall provide evidence to Sponsor that such insurance coverage has been obtained.

 

Sponsor shall secure and maintain in full force and effect throughout the performance of the Study insurance policies in such amounts and providing such coverage as is reasonable and customary for clinical development entities undertaking the Services contemplated by this Agreement.  If requested, Sponsor shall provide evidence to TKL that such insurance coverage has been obtained.

 

Section 12 - Record Retention

 

TKL shall retain the records and reports required by the Protocol for the longer of (a) five (5) years after delivery of a final report to the Sponsor or (b) such period as may be required by applicable law.  If requested by Sponsor in writing, TKL shall then deliver to the Sponsor all records and reports required by the Protocol (and, if not requested by Sponsor, those records may be destroyed).

 

Section 13 – Intellectual Property Ownership

 

All (a) Confidential Information belonging to Sponsor, including, but not limited to, confidential material, processes, trade secrets provide by Sponsor to TKL; (b) derivative works, updates or enhancements thereof or thereto; and (c) materials, documents and data resulting from the Services provide under this Agreement (the “Intellectual Property”), shall be deemed to be and remain Sponsor’s sole and exclusive property and Confidential Information belonging to Sponsor. TKL agrees to execute any documents or undertake any further actions if requested by Sponsor to evidence transfer of title to the Intellectual Property.  Intellectual Property shall be returned to Sponsor at any time upon its request but in no event later than thirty (30) days after the expiration or termination of this Agreement.  However, TKL is entitled to retain one copy of such Intellectual Property belonging to Sponsor, on a confidential basis for legal or regulatory purposes.

 

Neither party shall acquire any rights in or to any property owned or controlled by the other as a result of performance under this Agreement, except as expressly set forth in this 

 

4

 

Agreement.

 

This Section 13 shall survive termination or expiration of this Agreement.

 

Section 14 - Use of Investigational Material

 

TKL acknowledges that this Agreement constitutes a license to TKL by the Sponsor to use the Study materials and Sponsor’s confidential and proprietary information relating to the Study materials solely for the conduct of the Study as contemplated by this Agreement in accordance with the clinical Protocol and in accordance with FDA or other regulations defining the procedures, conditions and requirements applicable to investigational studies.  TKL will not make the Study materials available to any investigator other than those listed on FDA Form 1572 if required nor to any clinical or medical facility for use with patients not properly enrolled in the evaluation, except as otherwise provided for in this Agreement.

 

Section 15 - Monitoring

 

TKL agrees that the Sponsor or one of the Sponsor’s duly authorized representatives may visit TKL’s facilities to observe the progress of the Study and to discuss the work completed or in progress and to obtain copies of any written records maintained in the course of the Study providing such visits are made with reasonable notice to TKL.

 

Section 16 - Applicable Law

 

This Agreement and all terms, provisions and conditions of the Study and questions of the construction, validity and performance of this contract shall be governed by the laws of the State of New Jersey.  All disputes under this contract are to be decided according to New Jersey law.  The Parties agree that any suit, action, or proceeding with respect to this Agreement shall only be brought in the court of the United States of America for the District of New Jersey or the courts of the State of New Jersey, as the case may be, and by execution of this Agreement, the Parties irrevocably submit to such jurisdiction for that purpose.

 

Section 17 - Force Majeure

 

Either party shall be excused from performing its obligations under this Agreement to the extent its performance is delayed or prevented by any cause beyond the party’s reasonable control, including but not limited to, acts of God, fire, explosion, weather, disease, war, insurrection, governmental restriction, regulation or control, civil strife, riots, government action, strikes or power failure.  Performance shall be excused only to the extent of and during the reasonable continuation of such disability.  Any deadline or time for performance specified in the Protocol or SOW which falls due during or subsequent to the occurrence of any of the disabilities referred to herein shall be automatically extended for a period of time equal to the period of such disability.  The affected party will (a) promptly notify the other party if, by reason of any of the disabilities referred to herein, the affected party is unable to meet any deadline or time for performance specified in Protocol or SOW; (b)use commercially reasonable efforts to avoid or remove such causes of non-performance; and (c) continue performance with the utmost dispatch whenever such causes are removed.  In the case of a disability affecting TKL, if any part of the research is rendered invalid as a result of such disability, TKL will, upon written request from the Sponsor and, at the Sponsor’s cost and expense, repeat that part of the research affected by the disability.

 

5

 

Section 18 – Debarment

 

TKL represents and warrants for itself and its agents that, to the best of its knowledge, information, and belief, it is and they are not using, and will not use, in any capacity, in connection with the performance of the Services by TKL under this Agreement, the Services of any person debarred under subsections 306(A) or 306(B) of the Generic Drug Enforcement Act of 1992.  TKL shall disclose in writing to the Sponsor, as soon as reasonably practicable upon receiving actual notice thereof, the debarment of any employee or agent that is debarred or the existence of any action, suit, claim, investigation, or legal or administrative proceeding, pending or threatened, relating to the debarment of TKL or any person performing Services on behalf of TKL.

 

Section 19- Obligations and Indemnities

 

TKL represents and warrants that it shall perform all work required under this Agreement in a professional, diligent and careful manner in accordance with all applicable federal, state and local laws and regulations, and the terms and conditions set forth in the Protocol, applicable SOW, and this Agreement.  TKL shall accurately report the resulting data in a manner suitable to Sponsor and shall have no liability to anyone if it properly performs these duties in accordance with the terms of this Agreement and or any individual SOW.  In the event of any material error or failure by TKL to perform the Study which renders the Study invalid, TKL shall repeat the Study at TKL’s own expense or repay to the Sponsor the contract price to conduct the Study.  TKL shall not, under any circumstances, be liable for incidental or consequential damages attributable to any such error or failure to perform.  It is the purpose and intent of this Agreement that Sponsor shall evaluate the data submitted by TKL and shall make and be solely responsible for the decisions and policies made or to be made on the basis of these data; and shall bear all the liability, if any, arising out of such decisions and policies.

 

Sponsor agrees to defend, indemnify and hold harmless TKL, including its directors, shareholders, officers, physicians, investigators, agents and employees from any and all losses, damages, reasonable attorneys’ fees, costs, or medical expenses (a “Liability”) resulting from (a) breach of Sponsor’s representations and warranties under this Agreement; and (b) any action or inaction on the part of Sponsor which is a breach of this Agreement or any individual SOW, and (c) any claim, suit or proceeding brought by a third-party against TKL, solely as a result of TKL’s adherence to the terms of this Agreement or any individual SOW., related to this Agreement or any individual SOW.  If TKL, in the enforcement of any part of this Agreement, shall incur necessary medical or litigation expenses or become obligated to pay attorney’s fees or court costs, the Sponsor agrees to reimburse TKL for such expenses, counsel fees, or other costs within thirty days after receiving written notice from TKL of TKL’s incursion of same.  As a condition of this indemnification, TKL shall give Sponsor written notice of any claim made against TKL within five (5) days of receipt of same on the obligations indemnified against and provide Sponsor with cooperation and assistance to defend such claims at Sponsor’s expense.  The indemnity herein provided for will extend from the date of this Agreement to and including ten (10) years from the conclusion of the Study.

 

Sponsor’s liability under this agreement shall not include any Liability caused by: (a) failure of TKL to adhere to the terms of this Agreement, any individual SOW, the Protocol or Sponsor’s written instructions relative to the use of the Study product or the conduct of the Study; (b) failure of TKL to comply with any applicable federal, state or local laws or regulations including, but not limited to the regulations of the Federal Food and Drug Administration; (c) negligence or willful misconduct by TKL, including its directors, shareholders, officers, physicians, investigators, agents and employees.

 

6

 

TKL agrees to defend, indemnify, and hold harmless Sponsor including its directors, shareholders, officers, agents and employees from any Liability arising from or occurring as a result of (a) the negligence or willful misconduct of TKL; (b) breach of TKL’s representations and warranties under this agreement; and (c) any action or inaction on the part of TKL which is a breach of this Agreement or any individual SOW.  As a condition of this indemnification, Sponsor shall give TKL written notice of any claim made against Sponsor within five (5) days of receipt of same on the obligations indemnified against and provide TKL with cooperation and assistance to defend such claims at TKL’s expense.  The indemnity herein provided for will extend from the date of this Agreement to and including ten (10) years from the conclusion of the Study.

 

Section 20 - Publication Rights

 

Unless the Protocol provides otherwise, TKL may publish or publicly present Study results provided a copy of any proposed oral or written publication is approved by Sponsor in advance to submission for publication, which approval shall not be unreasonably withheld or delayed.  If the parties disagree concerning the appropriateness of the data analysis and presentation, TKL agrees to meet with Sponsor prior to submission for publication for the purpose of making good-faith efforts to discuss and resolve any issues or disagreement and, if necessary, to delay publication until such issues are resolved.  Neither party shall use the name of the other party for promotional purposes without the prior written consent of the party whose name is proposed to be used.

 

Section 21 - Notices

 

All notices, approvals or consents under this Agreement which are required or are permitted by this Agreement shall be in writing and shall be sent by United States mail or by telecopier by the parties as follows:

 

TKL Research, Inc.

One Promenade Boulevard, Suite 1101/1201

Fair Lawn, New Jersey 07410

 

Contact: Derek Grimes — Vice President, Clinical Operations

Telephone: (201) 587-0500;

Fax: (201) 881-8727

e-mail: dgrimes@tklresearch.com

 

Agile Therapeutics, Inc.

101 Poor Farm Road

Princeton, NJ 08540

 

Contact: Geoffrey Gilmore — General Counsel

Phone: (609) 356-1931

Fax: (609) 683-1855

Email: ggilmore@agiletherapeutics.com

 

Section 22 - Independent Contractor

 

In the performance of this Agreement, TKL shall be an independent contractor.

 

7

 

Neither party is authorized to act as the agent for the other and neither shall be bound by acts of the other.

 

Section 23 - Agreement Modification

 

This Agreement and/or any SOW may only be altered, amended or modified by a written document signed by both parties.  TKL will use commercially reasonable efforts to accommodate a request by Sponsor to amend or modify an SOW.  If such changes affect TKL’s costs, performance schedules or other provisions of the SOW, the prices and other affected provisions shall be equitably adjusted by agreement of TKL and Sponsor.

 

Section 24 - Assignment

 

Neither this Agreement nor the rights granted under this Agreement shall be assignable or otherwise transferable by either party without the prior consent of the other party; except that TKL and Sponsor may assign all of its rights and obligations hereunder to a third party as part of (a) an acquisition or merger of Sponsor; (b) the sale or transfer of substantially the entire business of Sponsor to which this Agreement relates; or (c) the arrangement of a strategic partnership, alliance or joint venture in which a third party acquires an interest in the business of Sponsor to which this Agreement relates.

 

8

 

Section 25 - Miscellaneous

 

Each party warrants and represents to the other party that it has full right and authority to enter into this Agreement.  If a provision of this Agreement is held to be invalid, the validity of the remainder of this Agreement will not be affected and the rights and obligations of the parties will be construed and enforced as if this Agreement did not contain the invalid provision.  The provisions of this Agreement and the application thereof are hereby declared to be severable.  Any waiver of any right or obligation hereunder must be in writing and signed by the Parties to be charge therewith.

 

This Agreement, together with the Exhibits or SOWs attached hereto and any agreement and other documents to be delivered pursuant hereto, constitutes the entire agreement between the Parties pertaining to the subject matter hereof and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, of the Parties, except for the Consultant Services Agreement entered into by the Parties on October 16, 2018.

 

In witness whereof, the parties hereto have caused this Agreement to be executed by their duly authorized representatives as of the date first above written.

 

	
TKL Research, Inc.
    	
 
    	
Agile Therapeutics, Inc.
    
	
One Promenade   Boulevard, Suite 1101/1201
    	
 
    	
101 Poor Farm Road
    
	
Fair Lawn, New Jersey   07410
    	
 
    	
Princeton, New Jersey   08540
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Derek Grimes
    	
 
    	
Al Altomari
    
	
Name
    	
 
    	
Name
    
	
 
    	
 
    	
 
    
	
Vice President,   Clinical Operations
    	
 
    	
Chairman & CEO
    
	
Title
    	
 
    	
Title
    
	
 
    	
 
    	
 
    
	
/s/ Derek Grimes
    	
 
    	
/s/ Al Altomari
    
	
Signature
    	
 
    	
Signature
    
	
 
    	
 
    	
 
    
	
October 26, 2018
    	
 
    	
October 26, 2018
    
	
Date
    	
 
    	
Date
    

 

9Exhibit 10.1

 

AMENDMENT NO. 3 TO LOAN AND SECURITY AGREEMENT

 

AMENDMENT
NO. 3 TO LOAN AND SECURITY AGREEMENT, dated as of February 5th, 2019 (this “Amendment No. 3”), is by and among
SECURUS 365, INC., a Delaware corporation, EVANCE, INC., a Delaware corporation, EVANCE CAPITAL, INC., a Delaware corporation,
OMNISOFT, INC., a Delaware corporation and CROWDPAY.US, INC., a New York corporation, as borrowers (each a “Borrower”
and collectively, “Borrowers”), THE OLB GROUP, INC., a Delaware corporation, as parent guarantor (“Parent
Guarantor”), the financial institutions or other entities from time to time party hereto, each as a Lender and GACP
FINANCE CO., LLC as agent for the Lenders (in such capacity, the “Agent”).

 

W
I T N E S S E T H :

 

WHEREAS,
Agent, Lenders, Borrowers and others have entered into financing arrangements pursuant to which Lenders (or Agent on behalf of
Lenders) have made and may make loans and advances and provide other financial accommodations to Borrowers as set forth in the
Loan and Security Agreement, dated as of April 9, 2018 (as amended, restated, amended and restated, supplemented or otherwise modified
from time to time, the “Credit Agreement”) and the other Loan Documents;

 

WHEREAS,
a Default has occurred under the Credit Agreement (the “Existing Default”) pursuant to Section 7.1(c) of the
Credit Agreement as a result of Borrowers’ failure to comply with the Financial Covenant set forth in Section 5.24(a) of
the Credit Agreement;

 

WHEREAS,
Section 10.5 of the Credit Agreement provides that, among other things, the Borrowers, the Agent and the Required Lenders may
(i) make certain amendments to the Credit Agreement and the other Loan Documents for certain purposes and (ii) waive or release
an Event of Default;

 

WHEREAS,
the Loan Parties have requested that Agent and the Lenders waive the Existing Default and make certain amendments to the Credit
Agreement, and Agent and the Lenders are agreeable to such request only on the terms and conditions set forth herein; and

 

WHEREAS,
by this Amendment No. 3, Agent, Lenders signatory hereto and Loan Parties signatory hereto intend to evidence such amendments;

 

NOW, THEREFORE,
in consideration of the foregoing and the mutual agreements and covenants contained herein, the parties hereto agree as follows:

 

1.      Interpretation.
For purposes of this Amendment No. 3, all terms used herein which are not otherwise defined herein, including, but not limited
to, those terms used in the recitals hereto, shall have the respective meanings assigned thereto in the Credit Agreement as amended
by this Amendment No. 3.

 

2.      Waiver
of Existing Default. In reliance upon the representations and warranties of the Loan Parties set forth in Section
4 below and subject to the conditions to effectiveness set forth in Section 5 below, Agent and the Lenders hereby irrevocably
waive the Existing Default. Each Loan Party acknowledges and agrees that (a) the waiver contained herein relates only to the
Existing Default and is effective solely for the purposes set forth herein and shall be limited precisely as written and
shall not be deemed to (x) waive, release, modify or limit any Loan Party’s obligations to otherwise comply with all
terms and conditions of the Credit Agreement and the other Loan Documents, (y) waive any other existing or future Events of
Default, or (z) prejudice any right or rights that Agent or the Lenders may have or may have in the future under or in
connection with the Credit Agreement or any other Loan Document (all of which rights and remedies are expressly reserved),
except as expressly provided herein, and (b) the granting of the waiver hereunder shall not impose or imply an obligation on
Agent or the Lenders to grant a waiver on any future occasion, whether on a similar matter or otherwise.

 

    1 

     

    

 

3.      Amendments.

 

(a)      Section 5.24(a) of the
Credit Agreement is hereby amended by replacing such Section 5.24(a) in its entirety to read:

 

(i) “(a)
(x) On or after the end of the first full fiscal month following the First Repayment until the fiscal month ended December 31,
2019, the ratio of (i) EBITDA for each fiscal month minus unfinanced Capital Expenditures (but not less than zero) for
such fiscal month, to (ii) Fixed Charges for such fiscal month (the “Fixed Charge Coverage Ratio”) shall
not be less than 1.10:1.00 and (y) on or after the end of the first full fiscal month ended January 31, 2020, the Fixed Charge
Coverage Ratio shall not be less than 1.20:1.00, measured in each case on a trailing twelve month basis from the Closing Date,
provided that for the first twelve months following the Closing Date, the Fixed Charge Coverage Ratio shall be tested on
a cumulative monthly basis for each month elapsed since the Closing Date; provided further that, solely for the purposes
of calculating the Fixed Charge Coverage Ratio, (x) EBITDA for each fiscal month ending on or before September 30, 2019 shall
include, in each case to the extent deducted in determining Net Income for the applicable period (x) fees, costs and expenses
incurred in connection with Equity Financings of the Loan Parties in an aggregate amount not to exceed $172,805.89 plus
(y) fees, costs and expenses incurred in connection with the [Acquisition] in an aggregate amount not to exceed $294,363.13 and
(y) EBITDA for each fiscal month ending after September 30, 2019 shall include, in each case to the extent deducted in determining
Net Income for the applicable period, fees costs and expenses incurred in connection with Equity Financings of the Loan Parties
in an aggregate amount for each Fiscal Year not to exceed $350,000.”

 

(b)      Schedule B to the Credit
Agreement is hereby amended by replacing the definition of “Fixed Charges” therein in its entirety to read:

 

““Fixed
Charges” means, for the period in question, on a consolidated basis, the sum of (i) all principal payments scheduled
to be made during or with respect to such period in respect of Indebtedness of the Loan Parties other than the Repayment, plus
(ii) all Interest Expense of the Loan Parties for such period paid or required to be paid in cash during such period, plus
(iii) all federal, state, and local income taxes of the Loan Parties paid or required to be paid for such period, plus (iv)
all cash distributions, dividends, redemptions and other cash payments made or required to be made during such period with respect
to Equity Interests issued by any Loan Party.”

 

4.      Representations
and Warranties. Each Loan Party, jointly and severally, hereby:

 

(a)      reaffirms all representations and warranties made to Agent and Lenders under the Credit Agreement and all of the other Loan
Documents and confirms that each of the representations and warranties made by Loan Parties in or pursuant to the Credit
Agreement, the other Loan Documents and any related agreements to which it is a party, and each of the representations and
warranties contained in any certificate, document or financial or other statement furnished at any time under or in
connection with this Agreement, the other Loan Documents or any related agreement shall be true and correct in all material
respects on and as of such date as if made on and as of such date (or to the extent any representations or warranties are
expressly made solely as of an earlier date, such representations and warranties shall be true and correct in all material
respects as of such earlier date); provided that any representation and warranty that is qualified as to
“materiality”, “Material Adverse Effect” or similar language shall be true and correct (after giving
effect to any qualification therein) in all respects on and as of such date;

 

    2 

     

    

 

(b)      reaffirms
all of the covenants contained in the Credit Agreement;

 

(c)      represents
and warrants that, other than the Existing Default, no Default or Event of Default has occurred and is continuing;

 

(d)      represents
and warrants that the execution, delivery and performance by each Loan Party of this Amendment No. 3 and the other documents,
agreements and instruments executed by any Loan Party in connection herewith (collectively, together with this Amendment No. 3,
the “Amendment Documents”) and the consummation of the transactions contemplated hereby or thereby, are within
such Loan Party’s powers, have been duly authorized by all necessary organizational action, and do not contravene (i) the
charter or by-laws or other organizational or governing documents of such Loan Party or (ii) any law or any contractual restriction
binding on or affecting any Loan Party, except, for purposes of this clause (ii), to the extent such contravention would not reasonably
be expected to have a Material Adverse Effect;

 

(e)      represents
and warrants that no authorization or approval or other action by, and no notice to or filing with, any Governmental Authority
or any other third party is required for the due execution, delivery and performance by any Loan Party of any Amendment Document
to which it is a party that has not already been obtained if the failure to obtain such authorization, approval or other action
could reasonably be expected to result in a Material Adverse Effect; and

 

(f)      represents
and warrants that each Amendment Document has been duly executed and delivered by each Loan Party thereto. This Amendment No. 3
constitutes, and each other Amendment Document will constitute upon execution, the legal, valid and binding obligation of each
Loan Party thereto enforceable against such Loan Party in accordance with its respective terms subject to the effect of any applicable
bankruptcy, insolvency, reorganization or moratorium or similar laws affecting the rights of creditors generally and subject to
general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

 

5.      Conditions
Precedent. This Amendment No. 3 shall be effective upon the satisfaction of each of the following conditions precedent:

 

(a)      Agent
shall have received counterparts of this Amendment No. 3, duly authorized, executed and delivered by Borrowers, Parent Guarantor,
Agent and the Required Lenders;

 

(b)      Other
than the Existing Default, no Default or Event of Default shall have occurred and be continuing; and

 

(c)      The
representations and warranties contained in Section 4 and in the Credit Agreement shall be true and correct in all material respects
on and as of such date as if made on and as of such date (except to the extent expressly relating to an earlier date, in which
case such representation and warranty shall be true and correct as of such earlier date).

 

6.      General.

 

(a)      Effect
of this Amendment No. 3. Except as expressly provided herein, no other consents, waivers, changes or modifications to
the Loan Documents are intended or implied, and in all other respects the Loan Documents are hereby specifically ratified,
restated and confirmed by all parties hereto as of the date hereof.

 

    3 

     

    

 

(b)      Fees.
Borrower agrees to pay on demand all expenses of Agent and Lenders in connection with the preparation, negotiation, execution,
delivery and administration of this Amendment No. 3.

 

(c)      Governing
Law. This Amendment No. 3 shall be governed by, and construed in accordance with, the laws of the State of New York, without
regard to conflicts of laws principles thereof.

 

(d)      Waiver
of Jury Trial. SECTION 10.16 OF THE CREDIT AGREEMENT IS HEREBY INCORPORATED BY REFERENCE INTO THIS AMENDMENT NO. 3 MUTATIS
MUTANDIS AND SHALL APPLY HERETO AS IF ORIGINALLY MADE A PART HEREOF.

 

(e)      Binding Effect. This Amendment No. 3 shall bind
and inure to the benefit of the respective successors and permitted assigns of each of the parties hereto.

 

(f)      Counterparts,
etc. This Amendment No. 3 may be executed in any number of counterparts and by different parties hereto in separate counterparts,
each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the
same agreement. Delivery of an executed counterpart of a signature page to this Amendment No. 3 by telecopier or by electronic
transmission of a pdf formatted counterpart shall be effective as delivery of a manually executed counterpart of this Amendment
No. 3.

 

(g)      Loan
Document. This Amendment No. 3 constitutes a Loan Document.

 

(h)      Reaffirmation.
Each of the undersigned Loan Parties acknowledges (i) all of its Obligations under the Credit Agreement and each other Loan Document
to which it is a party are reaffirmed and remain in full force and effect on a continuous basis, (ii) its grant of security interests
pursuant to the Loan Documents are reaffirmed and remain in full force and effect after giving effect to this Amendment No. 3,
(iii) the Obligations include, among other things and without limitation, the due and punctual payment of the principal of, interest
on, and premium (if any) on the Loans and (iv) except as expressly provided herein, the execution of this Amendment No. 3 shall
not operate as a waiver of any right, power or remedy of Agent or any Lender, constitute a waiver of any provision of any of the
Loan Documents or serve to effect a novation of the Obligations.

 

(i)      Release.
In consideration of the agreements of Agent and Lenders contained herein and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, each Loan Party signatory hereto, on behalf of itself and its
respective successors, assigns, and other legal representatives, hereby absolutely, unconditionally and irrevocably releases,
remises and forever discharges Agent and Lenders, and their successors and assigns, and their present and former
shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other
representatives (Agent, each Lender and all such other Persons being hereinafter referred to collectively as the
“Releasees” and individually as a “Releasee”), of and from all demands, actions, causes
of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings,
damages and any and all other claims, counterclaims, defenses, rights of set off, demands and liabilities whatsoever
(individually, a “Claim” and collectively, “Claims”) of every name and nature, known as
of the date of this Amendment No. 3, both at law and in equity, which each Loan Party signatory hereto, or any of its
respective successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against
the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at
any time on or prior to the day and date of this Amendment No. 3, in each case for or on account of, or in relation to, or in
any way in connection with any of the Credit Agreement, or any of the other Loan Documents or transactions thereunder or
related thereto.

 

 

[Remainder of Page Intentionally Left Blank]

 

    4 

     

    

 

 

IN WITNESS WHEREOF, the parties
hereto have caused this Amendment No. 3 to be duly executed and delivered by their authorized officers as of the day and year
first above written.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]